The urgent need for immunomodulatory treatment facilitated regulatory decisions due to rapidly emerging multisystem inflammatory syndrome (1,2). The syndrome emerged in children after the COVID-19 disease as a post-infection complication and due to the urgency in the requirement of the treatment the decision was made without proper understanding of